Pharming Group (OTCMKTS:PHGUF) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a note issued to investors on Tuesday.

According to Zacks, “Pharming Group NV develops innovative therapeutics for the treatment of genetic disorders, specialty products for surgical indications and nutritional products. The advanced technologies of the Company include innovative and validated platforms for the production of protein therapeutics, technology and processes for the purification and formulation of its products. Its primary product Ruconest (R) is a recombinant human C1 inhibitor approved for the treatment of angioedema attacks in patients with hereditary angioedema in the European Union countries, Norway, Iceland and Liechtenstein. Pharming Group NV is headquartered in Leiden, the Netherlands. “

A number of other equities analysts have also recently commented on the stock. ValuEngine cut shares of Pharming Group from a “hold” rating to a “sell” rating in a research report on Friday. HC Wainwright reaffirmed a “buy” rating on shares of Pharming Group in a research report on Thursday, October 26th.

Pharming Group (PHGUF) opened at $1.48 on Tuesday. The company has a debt-to-equity ratio of 11.72, a current ratio of 1.77 and a quick ratio of 1.27. Pharming Group has a 52-week low of $0.25 and a 52-week high of $1.58.

TRADEMARK VIOLATION WARNING: “Pharming Group (PHGUF) Rating Lowered to Hold at Zacks Investment Research” was originally posted by American Banking News and is the sole property of of American Banking News. If you are accessing this piece on another publication, it was illegally copied and republished in violation of U.S. and international trademark & copyright law. The legal version of this piece can be viewed at

About Pharming Group

Pharming Group NV (Pharming) is a Netherlands-based biotechnology company. The Company operates through two business segments, including Recombinant proteins, and DNage. Pharming focuses on the development, production and commercialization of human therapeutic proteins to be used as innovative therapies.

Get a free copy of the Zacks research report on Pharming Group (PHGUF)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Pharming Group NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharming Group NV and related companies with's FREE daily email newsletter.